A novel use for an old drug : resistance reversal in Candida albicans by combining dihydroartemisinin with fluconazole
Aim: To investigate the effects of dihydroartemisinin combined with fluconazole against C. albicans in vitro and to explore the underlying mechanisms. Materials & methods: Checkerboard microdilution assay and time-kill curve method were employed to evaluate the static and dynamic antifungal effects against C. albicans. Reactive oxygen species (ROS) was measured by a fluorescent probe. Results: Combination of dihydroartemisinin and fluconazole exerted potent synergy against planktonic cells and biofilms of fluconazole-resistant C. albicans, with the fractional inhibitory concentration index values less than 0.07. A potent fungistatic activity of this drug combination could still be observed after 18 h. The accumulation of ROS induced by the drug combination might contribute to the synergy. Conclusion: Dihydroartemisinin reversed the resistance of C. albicans to fluconazole.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Future microbiology - 16(2021) vom: 01. Mai, Seite 461-469 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Hui [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.12.2021 Date Revised 14.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fmb-2020-0148 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325126410 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325126410 | ||
| 003 | DE-627 | ||
| 005 | 20231225191757.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fmb-2020-0148 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM325126410 | ||
| 035 | |a (NLM)33960815 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Hui |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A novel use for an old drug |b resistance reversal in Candida albicans by combining dihydroartemisinin with fluconazole |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To investigate the effects of dihydroartemisinin combined with fluconazole against C. albicans in vitro and to explore the underlying mechanisms. Materials & methods: Checkerboard microdilution assay and time-kill curve method were employed to evaluate the static and dynamic antifungal effects against C. albicans. Reactive oxygen species (ROS) was measured by a fluorescent probe. Results: Combination of dihydroartemisinin and fluconazole exerted potent synergy against planktonic cells and biofilms of fluconazole-resistant C. albicans, with the fractional inhibitory concentration index values less than 0.07. A potent fungistatic activity of this drug combination could still be observed after 18 h. The accumulation of ROS induced by the drug combination might contribute to the synergy. Conclusion: Dihydroartemisinin reversed the resistance of C. albicans to fluconazole | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Candida albicans | |
| 650 | 4 | |a antimicrobial resistance | |
| 650 | 4 | |a biofilm | |
| 650 | 4 | |a dihydroartemisinin | |
| 650 | 4 | |a drug combination | |
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a fluconazole | |
| 650 | 4 | |a potential mechanism | |
| 650 | 4 | |a reactive oxygen species | |
| 650 | 4 | |a synergism | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Artemisinins |2 NLM | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a artenimol |2 NLM | |
| 650 | 7 | |a 6A9O50735X |2 NLM | |
| 650 | 7 | |a Fluconazole |2 NLM | |
| 650 | 7 | |a 8VZV102JFY |2 NLM | |
| 700 | 1 | |a Chen, Haisheng |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Wenna |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Jupeng |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Cunxian |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yuguo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future microbiology |d 2006 |g 16(2021) vom: 01. Mai, Seite 461-469 |w (DE-627)NLM171766504 |x 1746-0921 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2021 |g day:01 |g month:05 |g pages:461-469 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fmb-2020-0148 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2021 |b 01 |c 05 |h 461-469 | ||